Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COV-ENOX: Pharmacokinetics and concentration–effect of enoxaparin in ICU COVID-19 patients
2020-001823-15Phase 4Active
- Sponsor
- CHU Saint-Etienne
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enoxaparin in coronavirus disease 2019 (COVID-19) and venous thromboembolism (VTE), sponsored by CHU Saint-Etienne. Primary endpoint: Anti-Xa activity of enoxaparin. Started Apr 2020; status: active.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2020-001823-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001823-15.